The Latest Breaking News from PLRX

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.

Benzinga · Dec 4, 2025

3 Low-Rated POWR Stocks to Sell Immediately

The economic situation appears to be grim, with higher interest rates and the recent turmoil in the financial system causing sluggish growth in the first three months of this year. Hence, it could be wise to avoid struggling stocks Pliant Therapeutics (PLRX), Local Bounti (LOCL), and Kiromic BioPharma (KRBP). These…

StockNews.com · Apr 28, 2023

Read Why Pliant Therapeutics Shares Are Soaring Today

Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need.

Benzinga · Apr 13, 2022